You are here

FDA Agrees to Review Intranasal Gel Testosterone Product

Approval decision expected in February 2014 (July 9)

The FDA has accepted a new drug application (NDA) for CompleoTRT (Trimel Pharmaceuticals), a bioadhesive intranasal gel testosterone product for hypogonadal patients. The NDA is supported by efficacy and safety results from 306 patients who participated in a pivotal phase III study.

The agency set a target action date of February 28, 2014.

Subject to FDA approval, CompleoTRT is designed to be applied to the interior lateral wall of the nasal cavity, where studies have shown that the gel is fully absorbed into the nasal mucosa within 15 to 30 minutes.

It is expected that, as a result of the “no touch” targeted delivery to the nasal mucosa, the product should avoid skin-to-skin transference to spouses or other family members — a health risk that led the FDA to issue a black box warning in May 2009 for secondary transference for all topical testosterone gel preparations.

Source: Trimel Pharmaceuticals; July 9, 2013.

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut